On 22 December NewLink Genetics Corporation (NASDAQ:NLNK) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced that the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) has awarded NewLink Genetics’ wholly-owned subsidiary, BioProtection Systems, as the prime contractor in a $30 million contract to support the manufacturing and development activities of its investigational rVSV-EBOV (Ebola) vaccine candidate, including clinical development through a new 330-person Phase Ib study. NewLink Genetics Corporation (NASDAQ:NLNK) in last trading activity advanced 9.81% to close at $43.65. Company weekly performance is 11.69% while its quarterly performance stands at 82.25%. NewLink Genetics Corporation (NASDAQ:NLNK) is -18.38% away from its 52 week high.
Zacks upgraded shares of AOL Inc (NYSE:AOL) from an underperform rating to a neutral rating in a report issued on Friday. They currently have $47.20 target price on the stock. On last trading day AOL Inc. (NYSE:AOL) decreased -1.47% to close at $45.49. Its volatility for the week is 1.84% while volatility for the month is 2.72%. AOL’s sales growth for past 5 years was -11.00% and its EPS growth for past 5 years was 15.80%. AOL Inc. (NYSE:AOL) monthly performance is -1.24%.
Perficient Inc. (NASDAQ:PRFT) said that it has closed on its $35.7 million acquisition of Zeon Solutions Inc. of Milwaukee. Perficient Inc. (NASDAQ:PRFT) has 0.50% insider ownership while its institutional ownership stands at 68.10%. In last trading activity company’s stock closed at $18.54.
On 19 December RXi Pharmaceuticals Corporation (NASDAQ:RXII) announced that it has entered into an assignment and exclusive global license agreement with Hapten Pharmaceuticals, LLC for the therapeutic use of Samcyprone™. Samcyprone™ is a proprietary gel formulation of diphenylcyclopropenone (DPCP), an immunomodulating agent that works by initiating a T-cell response. Although DPCP is not a registered drug, it is used successfully by dermatologists as a topical immunomodulator to treat dermatological diseases. Samcyprone™ is expected to demonstrate an improved safety and use profile over DPCP as currently applied. On Friday shares of RXi Pharmaceuticals Corporation (NASDAQ:RXII) closed at $1.60.
On 23 December MAM Software Group, Inc. (NASDAQ:MAMS) said that it has announced the latest group of brands to join the lineup available through its Autocat+ Web-enabled catalog bringing the total brands available to 340. On last trading day MAM Software Group, Inc. (NASDAQ:MAMS) advanced 3.04% to close at $5.75. Its volatility for the week is 4.30% while volatility for the month is 4.44%. MAMS’s sales growth for past 5 years was 7.80% and its EPS growth for past 5 years was 16.50%. MAM Software Group, Inc. (NASDAQ:MAMS) monthly performance is -3.04%.